In vitro antifungal susceptibility of Candida spp. oral isolates from HIV positive patients and control individuals

Brazilian Oral Research

Volumn 25, Issue 1, 2011, Pages 28-33

  Brito, Graziella Nuernberg Back ^a   Inocêncio, Aline Cássia ^a   Querido, Sílvia Maria Rodrigues ^a   Jorge, Antonio Olavo Cardoso ^a   Koga Ito, Cristiane Yumi ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Antifungal agents; Candida; HIV

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; NYSTATIN;

ARTICLE; CANDIDA; CASE CONTROL STUDY; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TIME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; NYSTATIN; TIME FACTORS;

EID: 79952124578     PISSN: 18068324     EISSN: 18073107     Source Type: Journal    
DOI: 10.1590/S1806-83242011005000001     Document Type: Article

References (29)

1. Samaranayake LP, Fidel PL, Naglik JR, Sweet SP, Teanpaisan R, Coogan MM, et al. Fungal infections associated with HIV infection. Oral Dis. 2002;8 Suppl 2:151-60.
2. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005 Nov;43(11):5721-32.
3. Jabra-Rizk MA, Falkler WA Jr, Enwonwu CO, Onwujekwe DI Jr, Merz WG, Meiller TF. Prevalence of yeast among children in Nigeria and the United States. Oral Microbiol Immunol. 2001 Dec;16(6):383-5.
4. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005 Sep;56(3):532-7.
5. Lin AL, Johnson DA, Patterson TF, Wu Y, Lu DL, Shi Q, et al. Salivary anticandidal activity and saliva composition in a HIV-infected cohort. Oral Microbiol Immunol. 2001 Oct;16(5):270-8.
6. Al-Abeid HM, Khaled HA, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis. 2004 Dec;57(6):279-84.
7. Schorling SR, Kortinga HC, Froschb M, Mühlschlegel FA. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals. Crit Rev Microbiol. 2000;26(1):59-68.
8. Alves SH, Silva GM, Scopel PA, Oliveira LTO, Costa JM, Milan EP, et al. Isolamento de Candida dubliniensis da mucosa oral de um paciente com SIDA no Rio Grande do Sul. Rev AMRIGS. 2000 Jul-Dez;44(3,4):185-7.
9. Redding SW, Kirpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 2000 Sep-Oct;20(5): 178-81.
10. Crocco EI, Mimica LMJ, Muramatu LH, Garcia C, Suza VM, Ruiz LRB, et al. Identificação de espécies de Candida e susceptibilidade antifúngica in vitro: estudo de 100 pacientes com candidíases superficiais. An Bras Dermatol. 2004 Nov-Dez;79(6):689-97.
11. Ship JA, Vissink A, Chalacombe ST. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S6.e1-14.
12. Koga-Ito CY, Martins CAP, Loberto JCS, Santos SSF, Jorge AOC. In vitro antifungal susceptibility of Candida spp. Isolates from patients with chonic periodontitis and from control patients. Braz Oral Res. 2004 Jan-Mar;18(1):80-4.
13. Wingeter MA, Guilhermetti E, Shinobu CS, Takaki I, Svidzinski TIE. Identificação microbiológica e sensibilidade in vitro de Candida isoladas da cavidade oral de indivíduos HIV positivos. Rev Soc Bras Med Trop. 2007 May-Jun;40(3):272-6.
14. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, et al. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci. 2008 Sep;8(3):142-8.
15. White TC, Hollemann S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002 Jun;46(6):1704-13.
16. Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc. 2008;119:197-215.
17. Lewis RE, Kepser ME, Pfaller MA. Update on clinical antifungal susceptibility testing for Candida species. Pharmacotherapy. 1998 May-Jun;18(3):509-15.
18. Espinel-lgroff A. Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioter. 2000 Jun;13(2):161-6.
19. Samanarayake YH, Samanarayake LP. Candida krusei: biology, epidemiology, pathogenicity of Candida krusei and clinical manifestations of emerging pathogen. J Med Microbiol. 1994 Nov;41(5):295-310.
20. Back-Brito GN, Mota AJ, Vasconcellos TC, Querido SMR, Jorge AOC. Frequency of Candida spp. in the oral cavity of Brazilian HIV-positive patients and correlation with CD4 cell counts and viral load. Mycopathologia 2009 Feb;167(2):81-7.
21. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeast: approved standart. 2nd edition. Pennsylvania: NCCLS; 2002. 51 p.
22. Lyon JP, Moreira LM, Cardoso MAG, Saade J, Resende MA. Antifungal suscepitibility profile of Candida spp. oral isolates obtained from denture wearers. Braz J Microbiol. 2008 Dec;39(4):668-72.
23. Castro TL, Coutinho HDM, Gedeon CC, Santos JM, Santana WJ, Souza LBS. Mecanismos de resistência de Candida sp. a antifúngicos. Infarma. 2006;18(9/10):30-5.
24. st ed. Baltimore: William & Wilkins; 1998. 471 p.
25. Rautemaa R, Richardson M, Pfaller MA, Perheentupa J, Saxén H. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis. 2008;62(2):182-5.
26. Batista JM, Birman EG, Cury AE. Suscetibilidade a antifúngicos de cepas de Candida albicans isoladas de pacientes com estomatite protética. Rev Odontol Univ São Paulo. 1999;13(4):1-12.
27. Alves SH, Da Mata DA, Azevedo AC, Loreto ES, Boff E, Santurio JM, et al. In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida ssp. isolates. Mycoses. 2006;49(3):220-5.
28. Miotto NML, Yurgel LS, Cherubini K. Abordagem terapêutica da candidíase bucal. Sci Med. 2004;14(4):364-70.
29. Hamza OJ, Matee MI, Moshi MJ, Simon EN, Mugusi F, Mikx FH et al. Species distribuition and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol. 2008;8(135):1-9.